BRIEF-Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 Torrey Study In PAH

Reuters

Dec 06, 2022

Dec 6 (Reuters) - Gossamer Bio Inc :

* GOSSAMER BIO ANNOUNCES SERALUTINIB MEETS PRIMARY ENDPOINT IN PHASE 2 TORREY STUDY IN PAH

* GOSSAMER BIO INC - PRIMARY ENDPOINT, CHANGE IN PVR AT WEEK 24, MET WITH P-VALUE OF 0.0310

* GOSSAMER BIO INC- STATISTICALLY SIGNIFICANT IMPROVEMENTS OBSERVED IN NT-PROBNP AND ECHO MEASURES OF CARDIAC STRUCTURE AND FUNCTION

* GOSSAMER BIO INC - SECONDARY ENDPOINT, CHANGE IN 6MWD, NUMERICALLY FAVORED SERALUTINIB

* GOSSAMER BIO INC- SERALUTINIB WAS WELL TOLERATED AND AVOIDED HIGH FREQUENCY ADVERSE EVENTS OBSERVED IN IMATINIB IMPRES STUDY

* GOSSAMER BIO INC - CONSISTENTLY POSITIVE RESULTS SEEN ACROSS PRE-SPECIFIED SUB-GROUPS

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2289126809"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2289126809\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2289126809?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-12-06 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2289126809","market":"us","top_or_hot":-1,"title":"BRIEF-Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 Torrey Study In PAH","media":"Reuters","content":"<html><body><p>Dec 6 (Reuters) - Gossamer Bio Inc   :</p><p>   * GOSSAMER BIO ANNOUNCES SERALUTINIB MEETS PRIMARY ENDPOINT IN PHASE 2 TORREY STUDY IN PAH</p><p>   * GOSSAMER BIO INC - PRIMARY ENDPOINT, CHANGE IN PVR AT WEEK 24, MET WITH P-VALUE OF 0.0310</p><p>   * GOSSAMER BIO INC- STATISTICALLY SIGNIFICANT IMPROVEMENTS OBSERVED IN NT-PROBNP AND ECHO MEASURES OF CARDIAC STRUCTURE AND FUNCTION</p><p>   * GOSSAMER BIO INC - SECONDARY ENDPOINT, CHANGE IN 6MWD, NUMERICALLY FAVORED SERALUTINIB</p><p>   * GOSSAMER BIO INC- SERALUTINIB WAS WELL TOLERATED AND AVOIDED HIGH FREQUENCY ADVERSE EVENTS OBSERVED IN IMATINIB IMPRES STUDY</p><p>   * GOSSAMER BIO INC - CONSISTENTLY POSITIVE RESULTS SEEN ACROSS PRE-SPECIFIED SUB-GROUPS</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 Torrey Study In PAH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 Torrey Study In PAH\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-12-06 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Dec 6 (Reuters) - Gossamer Bio Inc   :</p><p>   * GOSSAMER BIO ANNOUNCES SERALUTINIB MEETS PRIMARY ENDPOINT IN PHASE 2 TORREY STUDY IN PAH</p><p>   * GOSSAMER BIO INC - PRIMARY ENDPOINT, CHANGE IN PVR AT WEEK 24, MET WITH P-VALUE OF 0.0310</p><p>   * GOSSAMER BIO INC- STATISTICALLY SIGNIFICANT IMPROVEMENTS OBSERVED IN NT-PROBNP AND ECHO MEASURES OF CARDIAC STRUCTURE AND FUNCTION</p><p>   * GOSSAMER BIO INC - SECONDARY ENDPOINT, CHANGE IN 6MWD, NUMERICALLY FAVORED SERALUTINIB</p><p>   * GOSSAMER BIO INC- SERALUTINIB WAS WELL TOLERATED AND AVOIDED HIGH FREQUENCY ADVERSE EVENTS OBSERVED IN IMATINIB IMPRES STUDY</p><p>   * GOSSAMER BIO INC - CONSISTENTLY POSITIVE RESULTS SEEN ACROSS PRE-SPECIFIED SUB-GROUPS</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GOSS","symbol_name":"Gossamer Bio Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2289126809","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2289126809","pubTimestamp":1670331277,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 6 (Reuters) - Gossamer Bio Inc   :   * GOSSAMER BIO ANNOUNCES SERALUTINIB MEETS PRIMARY ENDPOINT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GOSS":"Gossamer Bio Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"简介-Gossamer Bio宣布Seralutinib达到肺动脉高压2期Torrey研究的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOSS":0.9,"PAH":1},"content_text":"Dec 6 (Reuters) - Gossamer Bio Inc   :   * GOSSAMER BIO ANNOUNCES SERALUTINIB MEETS PRIMARY ENDPOINT IN PHASE 2 TORREY STUDY IN PAH   * GOSSAMER BIO INC - PRIMARY ENDPOINT, CHANGE IN PVR AT WEEK 24, MET WITH P-VALUE OF 0.0310   * GOSSAMER BIO INC- STATISTICALLY SIGNIFICANT IMPROVEMENTS OBSERVED IN NT-PROBNP AND ECHO MEASURES OF CARDIAC STRUCTURE AND FUNCTION   * GOSSAMER BIO INC - SECONDARY ENDPOINT, CHANGE IN 6MWD, NUMERICALLY FAVORED SERALUTINIB   * GOSSAMER BIO INC- SERALUTINIB WAS WELL TOLERATED AND AVOIDED HIGH FREQUENCY ADVERSE EVENTS OBSERVED IN IMATINIB IMPRES STUDY   * GOSSAMER BIO INC - CONSISTENTLY POSITIVE RESULTS SEEN ACROSS PRE-SPECIFIED SUB-GROUPSSource text for Eikon:    Further company coverage:","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}